- Home
- BCDA vs FEBO Comparison
BCDA vs FEBO Comparison
Compare BCDA & FEBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- FEBO
- Stock Information
- Founded
- BCDA N/A
- FEBO 1993
- Country
- BCDA United States
- FEBO Hong Kong
- Employees
- BCDA N/A
- FEBO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- FEBO
- Sector
- BCDA Health Care
- FEBO
- Exchange
- BCDA Nasdaq
- FEBO Nasdaq
- Market Cap
- BCDA 11.0M
- FEBO 12.6M
- IPO Year
- BCDA N/A
- FEBO 2023
- Fundamental
- Price
- BCDA $2.12
- FEBO $1.08
- Analyst Decision
- BCDA Strong Buy
- FEBO
- Analyst Count
- BCDA 1
- FEBO 0
- Target Price
- BCDA $25.00
- FEBO N/A
- AVG Volume (30 Days)
- BCDA 204.0K
- FEBO 14.6K
- Earning Date
- BCDA 08-12-2025
- FEBO 07-15-2025
- Dividend Yield
- BCDA N/A
- FEBO N/A
- EPS Growth
- BCDA N/A
- FEBO N/A
- EPS
- BCDA N/A
- FEBO N/A
- Revenue
- BCDA $3,000.00
- FEBO $17,110,653.00
- Revenue This Year
- BCDA N/A
- FEBO N/A
- Revenue Next Year
- BCDA N/A
- FEBO N/A
- P/E Ratio
- BCDA N/A
- FEBO N/A
- Revenue Growth
- BCDA N/A
- FEBO 11.58
- 52 Week Low
- BCDA $1.63
- FEBO $0.90
- 52 Week High
- BCDA $4.66
- FEBO $17.00
- Technical
- Relative Strength Index (RSI)
- BCDA 44.60
- FEBO 47.85
- Support Level
- BCDA $1.98
- FEBO $0.90
- Resistance Level
- BCDA $2.45
- FEBO $1.26
- Average True Range (ATR)
- BCDA 0.16
- FEBO 0.08
- MACD
- BCDA -0.01
- FEBO -0.00
- Stochastic Oscillator
- BCDA 18.00
- FEBO 49.44
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.